BACKGROUND: Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations. METHODS: A retrospective analysis was conducted of HIV-infected patients followed in an urban HIV clinic with an HIV RNA measurement < or =400 copies/mL on ART between January 1, 2003, and December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure (> or =1 HIV RNA measurement >400 copies/mL), unsanctioned stopping of ART, or loss to follow-up. Prior ART adherence and other baseline patient characteristics, determined at the time of the first suppressed HIV RNA load on or after January 1, 2003, were extracted from the electronic health record (EHR). Predictors of failure were assessed using proportional hazards modeling. RESULTS: Of 829 patients in the clinic, 614 had at least 1 HIV RNA measurement < or =400 copies/mL during the study period. Of these, 167 (27.2%) experienced treatment failure. Baseline characteristics associated with treatment failure in the multivariate model were: poor adherence (hazard ratio [HR] = 3.44; 95% confidence interval [CI]: 2.34 to 5.05), absolute neutrophil count <1000/mm (HR = 2.90, 95% CI: 1.26 to 6.69), not suppressed on January 1, 2003 (HR = 2.69, 95% CI: 1.78 to 4.07) or <12 months of suppression (HR = 1.64, 95% CI: 1.10 to 2.45), CD4 count <200 cells/mm (HR = 1.90, 95% CI: 1.31 to 2.76), nucleoside-only regimen (HR = 1.75, 95% CI: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% CI: 1.22 to 2.39) and > or =1 missed visit in the prior year (HR = 1.56, 95% CI: 1.13 to 2.16). CONCLUSIONS: More than one quarter of patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior ART adherence and other EHR data readily identify patient characteristics that could trigger specific interventions to improve ART outcomes.
BACKGROUND: Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations. METHODS: A retrospective analysis was conducted of HIV-infectedpatients followed in an urban HIV clinic with an HIV RNA measurement < or =400 copies/mL on ART between January 1, 2003, and December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure (> or =1 HIV RNA measurement >400 copies/mL), unsanctioned stopping of ART, or loss to follow-up. Prior ART adherence and other baseline patient characteristics, determined at the time of the first suppressed HIV RNA load on or after January 1, 2003, were extracted from the electronic health record (EHR). Predictors of failure were assessed using proportional hazards modeling. RESULTS: Of 829 patients in the clinic, 614 had at least 1 HIV RNA measurement < or =400 copies/mL during the study period. Of these, 167 (27.2%) experienced treatment failure. Baseline characteristics associated with treatment failure in the multivariate model were: poor adherence (hazard ratio [HR] = 3.44; 95% confidence interval [CI]: 2.34 to 5.05), absolute neutrophil count <1000/mm (HR = 2.90, 95% CI: 1.26 to 6.69), not suppressed on January 1, 2003 (HR = 2.69, 95% CI: 1.78 to 4.07) or <12 months of suppression (HR = 1.64, 95% CI: 1.10 to 2.45), CD4 count <200 cells/mm (HR = 1.90, 95% CI: 1.31 to 2.76), nucleoside-only regimen (HR = 1.75, 95% CI: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% CI: 1.22 to 2.39) and > or =1 missed visit in the prior year (HR = 1.56, 95% CI: 1.13 to 2.16). CONCLUSIONS: More than one quarter of patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior ART adherence and other EHR data readily identify patient characteristics that could trigger specific interventions to improve ART outcomes.
Authors: D Paris; B Ledergerber; R Weber; J Jost; M Flepp; M Opravil; C Ruef; S Zimmerli Journal: AIDS Res Hum Retroviruses Date: 1999-12-10 Impact factor: 2.205
Authors: Basit Chaudhry; Jerome Wang; Shinyi Wu; Margaret Maglione; Walter Mojica; Elizabeth Roth; Sally C Morton; Paul G Shekelle Journal: Ann Intern Med Date: 2006-04-11 Impact factor: 25.391
Authors: R Paredes; A Mocroft; O Kirk; A Lazzarin; S E Barton; J van Lunzen; T L Katzenstein; F Antunes; J D Lundgren; B Clotet Journal: Arch Intern Med Date: 2000-04-24
Authors: A Mocroft; B Ledergerber; J P Viard; S Staszewski; M Murphy; A Chiesi; A Horban; A-B E Hansen; A N Phillips; J D Lundgren Journal: J Infect Dis Date: 2004-10-28 Impact factor: 5.226
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: Amanda Mocroft; Lidia Ruiz; Peter Reiss; Bruno Ledergerber; Christine Katlama; Adriano Lazzarin; Frank-Detlef Goebel; Andrew N Phillips; Bonaventura Clotet; Jens D Lundgren Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Chanelle J Howe; Stephen R Cole; Sonia Napravnik; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero Journal: AIDS Res Hum Retroviruses Date: 2014-01-20 Impact factor: 2.205
Authors: E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter Journal: Antimicrob Agents Chemother Date: 2010-05-03 Impact factor: 5.191
Authors: Chanelle J Howe; Sonia Napravnik; Stephen R Cole; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero Journal: Am J Epidemiol Date: 2014-05-08 Impact factor: 4.897
Authors: Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2009-01-01 Impact factor: 3.731
Authors: Gregory K Robbins; William Lester; Kristin L Johnson; Yuchiao Chang; Gregory Estey; Dominic Surrao; Kimon Zachary; Sara M Lammert; Henry C Chueh; James B Meigs; Kenneth A Freedberg Journal: Ann Intern Med Date: 2012-12-04 Impact factor: 25.391
Authors: Marie Ballif; Bruno Ledergerber; Manuel Battegay; Matthias Cavassini; Enos Bernasconi; Patrick Schmid; Bernard Hirschel; Hansjakob Furrer; Martin Rickenbach; Milos Opravil; Rainer Weber Journal: PLoS One Date: 2009-12-14 Impact factor: 3.240